• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

深入了解先天性 A 型血友病中因子 VIII 抑制剂。

A close insight to factor VIII inhibitor in the congenital hemophilia A.

机构信息

a Haematology , Mashhad University of Medical sciences (MUMS) , Mashhad , Iran.

b Allergy Research Center, Ghaem hospital, School of Medicine , Mashhad University of Medical Sciences , Mashhad , Iran.

出版信息

Expert Rev Hematol. 2016 Sep;9(9):903-13. doi: 10.1080/17474086.2016.1208554. Epub 2016 Aug 16.

DOI:10.1080/17474086.2016.1208554
PMID:27367203
Abstract

INTRODUCTION

Hemophilia A (HA) has an X-linked pattern of inheritance and is the most common of the hemorrhagic disorders. HA is caused by a decreased or deficiency of the functional clotting factor VIII (FVIII) and effects 1 in 5000-10,000 male births. The common treatment for hemophilia is replacement therapy by plasma-derived or recombinant FVIII. Approximately 20-30% of people with a severe type of HA develop an inhibitor and this phenomenon is the main challenge in the management of these patients. Genetic factors and environmental determinants contribute to inhibitor development. Here, the roles of various genetic and environmental factors such as the type of FVIII concentrate used, the number of exposure days, and peak treatment time will be discussed in detail. It seems this information is helpful for hematologists.

AREAS COVERED

A literature review was done in January 2016 on PubMed and Scopus using the following keywords:' h(a)emophilia A & factor VIII inhibitor', 'h(a)emophilia A & factor VIII alloantibody', 'h(a)emophilia A & inhibitor'. There was no time limitation; however, there was an English language limitation placed on the articles selected. Expert commentary: Influential genetic and environmental factors in developing inhibitors have been discussed. Most of the risk factors are related to previously untreated patients with hemophili.

摘要

简介

血友病 A(HA)呈 X 连锁遗传,是最常见的出血性疾病之一。HA 是由功能性凝血因子 VIII(FVIII)减少或缺乏引起的,影响每 5000-10000 名男性出生中的 1 名。HA 的常见治疗方法是通过血浆衍生或重组 FVIII 进行替代疗法。大约 20-30%的严重型 HA 患者会产生抑制剂,这种现象是这些患者治疗管理的主要挑战。遗传因素和环境决定因素有助于抑制剂的发展。在这里,将详细讨论各种遗传和环境因素的作用,如所使用的 FVIII 浓缩物的类型、暴露天数和峰值治疗时间。这些信息似乎对血液学家有帮助。

涵盖领域

2016 年 1 月,在 PubMed 和 Scopus 上使用以下关键字进行了文献回顾:'h(a)emophilia A & factor VIII inhibitor'、'h(a)emophilia A & factor VIII alloantibody'、'h(a)emophilia A & inhibitor'。没有时间限制;但是,所选文章的语言限于英语。专家评论:已经讨论了产生抑制剂的有影响力的遗传和环境因素。大多数危险因素与未经治疗的血友病患者有关。

相似文献

1
A close insight to factor VIII inhibitor in the congenital hemophilia A.深入了解先天性 A 型血友病中因子 VIII 抑制剂。
Expert Rev Hematol. 2016 Sep;9(9):903-13. doi: 10.1080/17474086.2016.1208554. Epub 2016 Aug 16.
2
Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?2016年A型血友病中抑制物形成的预防。展望未来?
Thromb Res. 2016 Dec;148:96-100. doi: 10.1016/j.thromres.2016.10.024. Epub 2016 Oct 27.
3
Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.通过突变分析和因子 VIII 抗原测量预测 SIPPET 队列中因子 VIII 抑制剂的发展。
J Thromb Haemost. 2018 Apr;16(4):778-790. doi: 10.1111/jth.13961. Epub 2018 Mar 23.
4
[Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].[血友病抑制剂的研发及血友病患者的预防与管理策略]
Zhonghua Er Ke Za Zhi. 2013 Aug;51(8):631-4.
5
Inhibitors - cellular aspects and novel approaches for tolerance.抑制剂 - 细胞方面和新的耐受方法。
Haemophilia. 2014 May;20 Suppl 4(0 4):80-6. doi: 10.1111/hae.12407.
6
Inhibitors - genetic and environmental factors.抑制剂-遗传和环境因素。
Haemophilia. 2014 May;20 Suppl 4:87-93. doi: 10.1111/hae.12412.
7
The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.血友病抑制剂产生的多因素病因:遗传与环境。
Semin Thromb Hemost. 2009 Nov;35(8):723-34. doi: 10.1055/s-0029-1245105. Epub 2010 Feb 18.
8
Analysis of F8 inversions as risk factors for FVIII inhibitor development in Indian severe haemophilia A patients.印度重度甲型血友病患者中F8倒位作为FVIII抑制剂形成风险因素的分析
Blood Cells Mol Dis. 2014 Sep;53(3):161-3. doi: 10.1016/j.bcmd.2014.04.007. Epub 2014 May 11.
9
Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.边缘区B细胞对于A型血友病小鼠中凝血因子VIII抑制剂的形成至关重要。
Blood. 2017 Dec 7;130(23):2559-2568. doi: 10.1182/blood-2017-05-782912. Epub 2017 Oct 4.
10
Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.法国 Coag 队列分析支持在严重 A 型血友病男孩中,一种血浆源性和两种重组因子 VIII 品牌之间的免疫原性存在差异。
Haematologica. 2018 Jan;103(1):179-189. doi: 10.3324/haematol.2017.174706. Epub 2017 Oct 12.

引用本文的文献

1
Clinical Care of Bone Health in Patients on the Immune Tolerance Induction's Protocols With an Immunosuppressive Agent for Inhibitor Eradication in Hemophilia.血友病患者接受免疫耐受诱导方案联合免疫抑制剂以消除抑制剂的临床骨健康护理。
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620913951. doi: 10.1177/1076029620913951.
2
Is It Rational to Study Coagulations Test Routinely before Operations and Invasive Procedure: Single Center Retrospective Study.术前及侵入性操作前常规进行凝血功能检查是否合理:单中心回顾性研究
Int J Hematol Oncol Stem Cell Res. 2019 Oct 1;13(4):172-173.
3
Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies.
创新型和生物类似单克隆抗体的免疫原性
Antibodies (Basel). 2019 Mar 5;8(1):21. doi: 10.3390/antib8010021.